Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 d...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Delgado, Regina, de Miguel, Dunia, Bailen, Alicia, Ramon Gonzalez, Jose, Bargay Lleonart, Joan, Falantes, Jose F., Andreu, Rafael, Fernando, Ramosh, Tormo, Mar, Brunet, Salut, Figueredo, M. A., Casano, Javier, Medina, Angeles, Badiella, Llorenc, Fernandez Jurado, Antonio, Sanz, Guillermo, Asociacion Andaluza de Hematologia
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19996
Acceso en línea:http://hdl.handle.net/20.500.12105/19996
Access Level:acceso abierto
Palabra clave:Acute myeloid leukemia
Azacitidine
Dosing schedules
Myelodysplastic syndromes
Overall survival
Safety
Modelos de Riesgos Proporcionales
Síndromes Mielodisplásicos
Femenino
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Anciano
Anciano de 80 o más Años
Antimetabolitos Antineoplásicos
Estudios Retrospectivos
Adulto
Leucemia Mieloide Aguda
Antimetabolites, Antineoplastic
Descripción
Sumario:We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.

Similares en LA Referencia